Antiphospholipid syndrome

被引:1
作者
Specker, C.
机构
[1] Katholisches Krankenhaus St Josef, Klin Rheumatol, Zentrum Innere Med Klin Essen Sud, D-45239 Essen, Germany
[2] Katholisches Krankenhaus St Josef, Klin Immunol, Zentrum Innere Med Klin Essen Sud, D-45239 Essen, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2007年 / 66卷 / 01期
关键词
antiphospholipid syndrome; thromboembolism; anticardiolipin antibodies; anticoagulation; lupus anticoagulant;
D O I
10.1007/s00393-006-0127-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid syndrome (APS) is characterized by recurrent arterial or venous thromboembolism or pregnancy loss in association with antibodies directed against anionic phospholipids or plasma proteins bound to anionic phospholipids. A common cause of the huge variety of clinical manifestations is vaso-occlusive disease and not vasculitis in venous or arterial blood vessels of different sizes and sites (i.e. deep vein thrombosis, pulmonary embolism, cerebrovascular disease). In accordance with this, fetal abortion, typically beyond the tenth week of gestation, is also caused by infarctions of blood vessels in the placenta. Establishing the correct diagnosis of APS is not easy. To estimate the risk of thrombotic complications is challenging, as well as the questions of, which, how long and in what strength anticoagulation is recommended. This paper should enable the reader to apply international consensus classification criteria correctly, to interpret the different laboratory tests for anti-phospholipid antibodies and to gain an awareness of the different forms of anticoagulation in order to stratify therapeutic decisions.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 22 条
  • [1] BERMAS BL, 2006, CLIN MANIFESTATIONS
  • [2] BERMAS BL, 2006, PROGNOSIS THERAPY AN
  • [3] Bertolaccini ML, 1998, BRIT J RHEUMATOL, V37, P1229
  • [4] Neurological manifestations of antiphospholipid antibody syndrome
    Brey, RL
    Escalante, A
    [J]. LUPUS, 1998, 7 : S67 - S74
  • [5] Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Shoenfeld, Y
    Camps, MT
    Jacobsen, S
    Lakos, G
    Tincani, A
    Kontopoulou-Griva, I
    Galeazzi, M
    Meroni, PL
    Derksen, RHWM
    de Groot, PG
    Gromnica-Ihle, E
    Baleva, M
    Mosca, M
    Bombardieri, S
    Houssiau, F
    Gris, JC
    Quéré, I
    Hachulla, E
    Vasconcelos, C
    Roch, B
    Fernández-Nebro, A
    Boffa, MC
    Hughes, GRV
    Ingelmo, M
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (04): : 1019 - 1027
  • [6] A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
    Erkan, D
    Yazici, Y
    Peterson, MG
    Sammaritano, L
    Lockshin, MD
    [J]. RHEUMATOLOGY, 2002, 41 (08) : 924 - 929
  • [7] FEINSTEIN DI, 1972, PROGR HEMOSTASIS THR, P75
  • [8] Fischer-Betz R, 2003, AKTUEL RHEUMATOL, V28, P131
  • [9] ANTICARDIOLIPIN ANTIBODIES AND THE RISK FOR ISCHEMIC STROKE AND VENOUS THROMBOSIS
    GINSBURG, KS
    LIANG, MH
    NEWCOMER, L
    GOLDHABER, SZ
    SCHUR, PH
    HENNEKENS, CH
    STAMPFER, MJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1992, 117 (12) : 997 - 1002
  • [10] Girón-González JA, 2004, J RHEUMATOL, V31, P1560